Oragenics, Inc. — 2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012; filed March 26, 2013. The company develops antibiotic and oral-health products and markets ProBiora3 probiotic products. Its lead antibiotic candidate, MU1140, remains preclinical.
Financial performance and liquidity
| Metric | 2012 | 2011 |
|---|---|---|
| Revenue | $1.332 million | $1.444 million |
| Cost of sales | $878,461 | $713,627 |
| Gross profit | $453,303 | $730,820 |
| Research and development | $7.861 million | $2.449 million |
| Selling, general and administrative | $5.025 million | $5.628 million |
| Operating loss | $12.432 million | $7.346 million |
| Net loss | $13.090 million | $7.679 million |
| Net cash used in operations | $5.212 million | $5.495 million |
- Fourth-quarter revenue was $430,582, up from $396,590; net loss was $1.989 million versus $1.939 million. Fourth-quarter cost of sales rose to $403,935, largely due to inventory scrap and reserves.
- Annual ProBiora3 sales were $1.195 million, down from $1.230 million. Total revenue also included grant revenue.
- 2012 R&D included a one-time, noncash $5.798 million charge for 4,392,425 shares issued to Intrexon. Excluding that charge, R&D expense was lower year over year.
- Cash and cash equivalents were $9.926 million at year-end, with $61,763 in restricted cash. Working capital was positive $9.147 million, compared with a deficit of $8.328 million in 2011. Management estimated available cash would fund its operating plan through March 2014; additional funding is expected to be necessary.
- Year-end current liabilities were $1.256 million, including $47,977 of short-term notes; the $7.5 million shareholder revolving note reported in 2011 had been exchanged for equity. Total shareholders’ equity was $9.232 million, versus a deficit of $8.179 million.
- Financing activities provided $14.977 million in cash. The July 2012 share offering raised approximately $13 million gross, or approximately $12.046 million net; debt to the Koski Family Limited Partnership (KFLP) was also converted into shares. Outstanding common shares increased from 5.894 million to 27.383 million during 2012.
Material changes and business developments
- Revenue declined 7.8% year over year, while net loss widened 70.5%. R&D growth was principally attributable to the noncash Intrexon share issuance; cost of sales also rose, including higher inventory scrap expense.
- The June 2012 Intrexon collaboration aims to develop and manufacture MU1140 and other lantibiotics. The company reported improved fermentation yields and a new purification process, but still needs additional manufacturing capacity and successful preclinical work.
- Management expected to begin MU1140 or analog preclinical studies in the second half of 2013 and, if successful, to file an FDA Investigational New Drug application by the first quarter of 2015. These are expectations, not assured milestones.
- ProBiora3 efforts were refocused on direct-to-consumer and dental-professional channels. Preliminary University of Washington study data were inconclusive; another clinical study and a two-year Scandinavian pediatric study were underway.
- The company discontinued its Phase 1b SMaRT Replacement Therapy trial because restrictive enrollment criteria made recruitment difficult, and shifted toward seeking a partner. It also seeks partners for LPT3-04, a weight-loss candidate.
Outlook, risks and unusual items
- The company reported recurring losses and negative operating cash flow since inception, a $54.086 million accumulated deficit, and no assurance it can obtain additional financing on acceptable terms. Management expects substantial future losses and rising development costs.
- MU1140 has not entered human trials and is subject to manufacturing, preclinical, clinical and regulatory uncertainty. ProBiora3 is the only product currently generating product revenue, which remains modest.
- Key dependencies include Intrexon and contract manufacturers, limited supplier redundancy, the terms and continuing performance of technology licenses, FDA regulation, and the ability to raise capital. The UFRF licenses require annual minimum R&D spending and royalty payments; failure to meet obligations could put the licenses at risk.
- The Intrexon agreement includes a 25% share of gross profits from covered product sales, 50% of sublicensing revenue, and potential equity milestone issuances. The company issued Intrexon 4.392 million shares upfront; future milestones could further dilute shareholders.
- Management assessed internal control over financial reporting as ineffective at year-end due to a material weakness in segregation of duties, despite remediation efforts. Disclosure controls were reported effective. The independent auditor gave an unqualified opinion on the financial statements and did not attest to internal-control effectiveness.
- No material legal proceedings or off-balance-sheet arrangements were reported. The company paid no dividends and did not expect to pay them in the foreseeable future.
Important facts for investors to verify
- Cash use and financing needs against management’s stated March 2014 cash runway, including availability and terms of any new capital.
- Progress, cost and manufacturability of the Intrexon program, and whether MU1140 preclinical and IND milestones are achieved.
- ProBiora3 sales trends, gross economics, returns and inventory reserves; assess the significance of inconclusive study results and channel expansion plans.
- Potential dilution from shares, warrants, options and Intrexon milestone or participation rights; verify current share count and ownership concentration.
- Remediation of the segregation-of-duties material weakness and continued compliance with UFRF license spending and payment requirements.